Please login to the form below

Not currently logged in
Email:
Password:

Lilly partners with Wal-Mart

Eli Lilly has partnered with retailer Wal-Mart to sell an affordable version of the pharma company's Humulin synthetic human insulin product for diabetes

Eli Lilly has partnered with Wal-Mart, the country's largest retailer, to sell an affordable version of the pharma company's Humulin synthetic human insulin product for diabetes in nationwide Wal-Mart pharmacies. The deal represents the first time that Lilly has partnered with a retail pharmacy on a co-branded product.

The product, which will be available to consumers starting in mid-September, will be sold under the dual-branded name Humulin ReliOn.

Wal-Mart, which has more than 4,300 US stores, already offers a number of $9 diabetes management products under the ReliOn brand, including the ReliOn Ultima Blood Glucose Meter, ReliOn Ultima Blood Glucose Test Strips, and the ReliOn A1c test.

Lilly's Humulin generated worldwide sales of $1bn last year, but is being overshadowed by an even bigger moneymaker, the company's newer Humalog insulin, which brought in $2bn during the same period.

23rd June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics